ArticleBMJ open2026
Feasibility, use and usability of an adapted mHealth tool for dementia risk reduction among middle-aged and older adults in Germany: protocol for a non-randomised pilot study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSeveral potentially modifiable factors are associated with the risk of cognitive decline and dementia, indicating potential for risk reduction via lifestyle modifications. While multidomain interventions targeting lifestyle changes for dementia risk reduction are often highly selective and resource-intensive, eHealth/mHealth interventions offer a potentially low-cost, scalable approach to promote brain-healthy lifestyles for a large number of individuals. This protocol outlines a pilot study to test an mHealth intervention for dementia risk reduction among middle-aged to older adults in Germany. METHODS AND ANALYSIS: We will translate and adapt the smartphone-based intervention MyBraincoach for dementia risk reduction, developed at Maastricht University in the Netherlands, to the German healthcare setting and test the app in a 12-week, non-randomised pre-post pilot study. Key feasibility outcomes include feasibility and success of recruitment, use and usability of the app. Exploratory outcomes include changes in dementia risk profiles, dementia literacy, health-related quality of life, self-efficacy and motivation for behaviour change. A sample of n=75 adults aged 40-75 years will be recruited across Germany, using diversified convenience sampling. Data will be collected using web-based questionnaires at baseline and follow-up after 12 weeks. Feasibility and success of recruitment, including recruitment rates and sample characteristics, will be evaluated descriptively. Changes in dementia risk profiles and other secondary outcomes will be investigated using dependent-samples t-tests and McNemar's tests as appropriate. Lastly, a moderated remote focus group will be conducted with n=8 participants of the pilot study to gain insights on the target group's experiences with usage of the app and to assess suggestions for modification and improvement. Respective data will be analysed using structured content analysis. ETHICS AND DISSEMINATION: Ethical approval was obtained from the Ethics Committee of the Medical Faculty of Leipzig University (ref.: 476/22-ek). Findings will be disseminated via peer-reviewed publications, presentation at (inter)national scientific conferences and social media channels, respectively. Results will inform design and sample size of a confirmatory randomised controlled trial to assess effectiveness of the intervention. TRIAL REGISTRATION NUMBER: German Clinical Trials Register (DRKS00038349).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.